The effect of oligonucleotides to c-myb on vascular smooth muscle cell proliferation and neointima formation after porcine coronary angioplasty

Circulation Research

Volumn 80, Issue 4, 1997, Pages 520-531

  Gunn, Julian ^a,b   Holt, Cathy M ^a   Francis, Sheila E ^a   Shepherd, Lynda ^a   Grohmann, Malcolm ^a   Newman, Christopher M H ^a   Crossman, David C ^a   Cumberland, David C ^a  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b NORTHERN GENERAL HOSPITAL   (United Kingdom)

Author keywords

antisense oligomer; c myb; local delivery; restenosis; smooth muscle cell proliferation

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; OLIGODEOXYNUCLEOTIDE PHOSPHOROTHIOATE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERY INJURY; ARTERY INTIMA PROLIFERATION; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY; GENE EXPRESSION; NONHUMAN; ONCOGENE C FOS; ONCOGENE C MYB; PRIORITY JOURNAL; SWINE; TRANSLUMINAL CORONARY ANGIOPLASTY; VASCULAR SMOOTH MUSCLE;

EID: 0030977841     PISSN: 00097330     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.RES.80.4.520     Document Type: Article

References (51)

1. Popma JJ, Califf RM, Topol EJ. Clinical trials of restenosis after coronary angioplasty. Circulation. 1991;84:1426-1436.
2. Macleod DC, Strauss BH, De Jong M, Escaned J, Umans VA, van Suylen RJ, Verkerk A, de Feyter PJ, Serruys PW, Proliferation and extracellular matrix synthesis of smooth muscle cells cultured from human coronary atherosclerotic and restenotic lesions. J Am Coll Cardiol. 1994;23:59-65.
3. Glagov S. Intimal hyperplasia, vascular modeling, and the restenosis problem. Circulation. 1994;89:2888-2891.
4. Schwartz R, Holmes D, Topol E. The restenosis paradigm revisited: an alternative proposal for cellular mechanisms. J Am Coll Cardiol. 1992;20:1284-1293.
5. Mintz G, Pichard A, Kent K, Satler L, Popma J, Wong S, Painter J, DeForty D, Leon M. Endovascular stents reduce restenosis by eliminating geometric arterial remodelling: a serial intravascular ultrasound study. J Am Coll Cardiol. 1995;(Feb suppl):36A. Abstract.
6. Serruys PW, de Jaegere P, Kiemeneij F, Macaya C, Rutsch W, Heyndrickx G, Emanuelsson H, Marco J, Legrand V, Materne P, Belardi J, Sigwart U, Colombo A, Goy J, van den Heuvel P, Delcan J, Morel M-A. A comparison of balloon-expandable stent implantation with balloon angioplasty in patients with coronary artery disease. N Engl J Med. 1994;331:489-495.
7. Fischman D, Leon M, Baim D, Schatz R, Savage M, Penn I, Detre K, Veltri L, Ricci D, Nobuyoshi M, Cleman M, Heuser R, Almond D, Teirstein P, Fish D, Colombo A, Brinker J, Moses J, Shaknovich A, Hirshfeld J, Bailey S, Ellis S. Rake R, Goldberg S. A randomised comparison of coronary stent placement and balloon angioplasty in the treatment of coronary artery disease, N Engl J Med. 1994;331:496-501.
8. Camenzind E, Kint P-P, DiMario C, Ligthart J, van der Giessen W, Boersma E, Serruys PW. Intracoronary heparin delivery in humans. Circulation. 1995;92:2463-2472.
9. Topol EJ, Califf RM, Weisman HF, Ellis SG, Teheng JE, Worley S, Ivanhoe R, George BS, Fintel D, Weston M, Sigmon K, Anderson KM, Lee KL, Willerson JT. Randomised trial of coronary inter- vention with antibody against platelet IIb/IIIa integrin for reduction of clinical restenosis: results at six months. Lancet. 1994;343:881-886.
10. Emanuelson H, Beatt KJ, Bagger J-P, Balcon R, Heikkila J, Piessens J, Schaeffer M, Suryapranata H, Foegh M, Long-term effects of angiopeptin treatment in coronary angioplasty. Circulation. 1995;91:1689-1696.
11. Bauters C, de Groote P, Adamantidis M, Delcayre C, Hamon M, Lablanche J-M, Bertrand ME, Dupuis B, Swynghedauw B. Protooncogene expression in rabbit aorta after wall injury: first marker of the cellular process leading to restenosis after angioplasty? Eur Heart J. 1992;13:556-559.
12. Brown KE, Kindy MS, Sonenshein GE. Expression of the c-myb proto-oncogene in bovine vascular smooth muscle cells. J Biol Chem. 1992;267:4625-4630.
13. Muscovici C, Leukaemic transformation with avian myeloblastosis virus: present status. Curr Top Micrabiol Immunol. 1975;71:79-101.
14. Gonda T, Gough N, Dunn A, de Blaquiere J. A nucleotide sequence of cDNA clones of the murine myb proto-oncogene. EMBO J. 1985;4:2003-2008.
15. Thiele CJ, Cohen PS, Israel MA, Regulation of c-myb expression in human neuroblastoma cells during retinoic acid-induced differentiation. Mol Cell Biol. 1988;8:1677-1683.
16. Majello B, Kenyon LC, Dalla-Favera R. Human c-myb protooncogene: nucleotide sequence of cDNA and organization of the genomic locus. Proc Natl Acad Sci U S A. 1986;83:9636-9640.
17. Thompson CB, Challoner PB, Neiman PE, Groudine M. Expression of the c-myb proto-oncogene during cellular proliferation. Nature. 1986;19:374-380.
18. 1 phase of the cell cycle. J Biol Chem. 1989;264:6990-6995.
19. Morishita R, Gibbons GH, Ellison KE, Nakajima M, Zhang L, Kaneda Y, Ogihara T, Dzau VJ. Single intramural delivery of antisense cdc2 kinase and proliferating cell nuclear antigen ODNs results in chronic inhibition of neointimal hyperplasia. Proc Natl Acad Sci U S A. 1993;90:8474-8478.
20. Speir E, Epstein SE. Inhibition of smooth muscle cell proliferation by an antisense oligodeoxynucleotide targeting the messenger RNA encoding proliferating cell nuclear antigen. Circulation. 1992;86:538-547.
21. Simons M, Rosenberg RD, Antisense nonmuscle myosin heavy chain and c-myb oligonucleotides suppress smooth muscle cell proliferation in vitro. Circ Res. 1992;70:835-843.
22. Biro S, Fu YM, Yu ZX, Epstein SE. Inhibitory effects of antisense oligodeoxynucleotides targeting c-myc mRNA on smooth muscle cell proliferation and migration. Proc Natl Acad Sci U S A. 1993;90:654-658.
23. Shi Y, Hutchinson HG, Hall DJ, Zalewski A. Downregulation of c-myc expression by antisense oligonucleotides inhibits proliferation of human smooth muscle cells. Circulation. 1993:88:1190-1195.
24. Bennett MR, Anglin S, McEwan JR, Jagoe R, Newby AC, Evan GI. Inhibition of vascular smooth muscle cell proliferation in vitro and in vivo by c-myc antisense oligodeoxynucleotides. J Clin Invest. 1994;93:820-828.
25. Edelman ER, Simons M, Sirois MG, Rosenberg RD. c-myc in vasculoproliferative disease. Circ Res. 1995;76:176-182.
26. Shi Y, Fard A, Galeo A, Hutchinson HG, Vermani P, Dodge GR, Hall DJ, Shaheen F, Zalewski A. Transcatheter delivery of c-myc antisense oligomers reduces neotimal formation in a porcine model of coronary artery balloon injury. Circulation. 1994;90:944-951.
27. Morishita R, Gibbons GH, Ellison KE, Nakajima M, von der Leyen H, Zhang L, Kaneda Y, Ogihara T, Dzau VJ. Intimal hyperplasia after vascular injury is inhibited by antisense cdc 2 kinase ODNs. J Clin Invest. 1994;93:1458-1464.
28. Riessen R, Hogan J, Pastore C, Karsch K, Isner J. Local delivery of c-myb antisense ODNs for the prevention of restenosis in atherosclerotic rabbits. Eur Heart J. 1994;15(suppl):380. Abstract.
29. Simons M, Edelman ER, Dekeyser JL, Langer R, Rosenberg RD. Antisense c-myb ODNs inhibit intimal arterial smooth muscle cell accumulation in vivo. Nature. 1992;359:67-70.
30. Villa AE, Guzman LA, Poptic EJ, Labhasetwar V, D'Souza S, Farrell CL, Plow EF, Levy RJ, DiCorleto PE, Topol EJ. Effects of antisense c-myb oligonucleotides on vascular smooth muscle cell proliferation and response to vessel wall injury. Circ Res. 1995;76:505-513.
31. Bennett MR, Schwartz SM. Antisense therapy for angioplasty restenosis; some critical considerations. Circulation. 1995;92:1981-1993.
32. Black LE, Farrelly JG, Cavsgnaro JA, Ahn C-H, DeGeorge JJ, Taylor AS, DeFelice AF, Jordan A. Regulatory considerations for oligonucleotide drugs: updated recommendations tor pharmacology and toxicology studies. Antisense Res Dev. 1994;4:299-301.
33. Wolinsky H, Thung SN. Use of perforated balloon catheter to deliver concentrated heparin into the wall of the normal canine artery. J Am Coll Cardiol. 1990;15:475-481.
34. Chomczynski P, Sacchi N. Single step method of RNA isolation by acid guanidinium thiocyanate phenol-chloroform extraction. Anal Biochem. 1987;162:156-159.
35. Francis SE, Duff GW. p7B6, a ubiquitous RNA with homology to the ribosomal RNA L41. Nucleic Acids Res. 1993;21:2944-2945.
36. Humphrey W, Simmons C, Toombs C, Shebuski R. Induction of neointimal hyperplasia by coronary angioplasty balloon overin-flation: comparison of feeder pigs to Yucatan minipigs. Am Heart J. 1994;127:20.31.
37. Gunn J, Holt C, Francis S, Shepherd L, Grohmann M, Crossman D, Cumberland D. Restenosis after baloon angioplasty: intimal hyperplasia or vessel remodeling? Heart. 1996;75:P27. Abstract.
38. Woolf TM, Melton DA, Jennings CJB. Specificity of antisense oligonucleotides in vitro. Proc Natl Acad Sci U S A. 1992;89:7305-7309.
39. Burgess TL, Fisher EF, Ross SL, Ready JV, Qian Y-X, Bayewitch LA, Cohen AM, Herrera CJ, Hu SS-F, Kramer TB, Lott FD, Martin FH, Pierce GF, Simonet L, Farrell CL, The antiproliferative activity of c-myb and c-myc antisense oligonucleotides in smooth muscle cells is caused by a non-antisense mechanism. Proc Natl Acad Sci U S A. 1995;92:4051-4055.
40. Wang W, Chen HJ, Schwartz A, Cannon P, Stein C, Rabbani LE. Sequence-independent inhibition of in vitro vascular smooth muscle cell proliferation, migration, and in vivo neointimal formation by phosphorothioate oligonucleotides. J Clin Invest, 1996;98:443-450.
41. Maltese J, Sharma H, Vassilev L, Naraygnan R. Sequence context of antisense RelA/NF-κB phosphorothioates determines specificity. Nucleic Acids Res. 1995;23:1146-1151.
42. Donis-Keller H. Site-specific cleavage of RNA, Nucleic Acids Res. 1979;7:179-192.
43. Mizuno T, Chou M-Y, Inouye M. A unique mechanism regulating gene expression: translational inhibition by a complementary RNA transcript (micRNA). Proc Natl Acad Sci U S A. 1984;81:1966-1970.
44. Krieg AM, Yi A-K, Matson S, Waldschmidt T, Bishop G, Teasdale R, Koretsky G, Klinman D. CpG motifs in bacterial DNA trigger direct B cell activation. Nature. 1995;374:546-548.
45. Wickstrom E, Antisense DNA therapeutics: neutral analogs and their stereochemistry. In: Erickson R, Izant J, eds. Gene Regulation: Biology of Antisense RNA and DNA. New York, NY: Raven Press Publishers; 1992:261-272.
46. Milligan JF, Matteucci MD, Martin JC, Current concepts in antisense drug design. J Modern Chem. 1993;36:1924-1937.
47. Hoke GD, Draper K, Freier SM, Gonzalez C, Driver VB, Zounes MC, Ecker DJ. Effects of phosphorothioate capping on antisense obligonucleotide stability, hybridization and antiviral efficacy versus herpes simplex virus infection. Nucleic Acids Res. 1991;19:5743-5748.
48. Guvakova MA, Yakubov LA, Vlodavsky I, Tonkinson JL, Stein CA, Phosphorothioate oligodeoxynucleotides bind to basic fibroblast growth factor, inhibit its binding to cell surface receptors, and remove it from low affinity binding sites on extracellular matrix. J Biol Chem. 1995;270:2620-2627.
49. Pickering JG, Isner JM, Ford CM, Weir L, Lazarovits A, Rocnik E, Chow L. Processing of chimeric antisense oligonucleotides by human vascular smooth muscle cells and human atherosclerotic plaque. Circulation. 1996;93:772-870.
50. French J, Jennings M, Florey H. Morphological studies on atherosclerosis in swine. Ann N Y Acad Sci. 1965;127;780-799.
51. Schwartnz RS, Murphy JG, Edwards WD, Camrud AR, Vliestra RE, Holmes DR. Restenosis after balloon angioplasty; a practical proliferative model in porcine coronary arteries. Circulation. 1990;82:2190-2200.